Pulmonary Hypertension and Multiple Myeloma

Carlo Rostagno; Rostagno Perfetto

doi:doi:10.11648/j.cmr.20130204.17

| Peer-Reviewed

Pulmonary Hypertension and Multiple Myeloma

Carlo Rostagno, Rostagno Perfetto

Published in Clinical Medicine Research (Volume 2, Issue 4)

Received: 8 June 2013 Published: 20 July 2013

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

The relationships between pulmonary hypertension multiple myeloma, monoclonal protein and finally drug treatment of plasma cell diseases are complex and not fully elucidated. Pulmonary hypertension has been reported as a rare complication of multiple myeloma (MM), more frequently in patients with POEMS syndrome. More recently pulmonary hypertension has been described during thalidomide treatment for refractory MM. We report a case of severe pulmonary hypertension associated with MM, pleural and cardiac amyloidosis. A revision of literature follows.

Published in	Clinical Medicine Research (Volume 2, Issue 4)
DOI	10.11648/j.cmr.20130204.17
Page(s)	73-76
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2013. Published by Science Publishing Group

Keywords

Multiple Myeloma, Pulmonary Hypertension, Thalidomide

References

[1]	GShiue ST, McNally DP. Pulmonary hypertension from prominent vascular involvement in diffuse amyloidosis. Arch Intern Med. 1988 ;148(3):687-9
[2]	Lehtonen J, Kettunen P. Pulmonary hypertension as a dominant clinical picture in a case of amyloidosis and smoldering multiple myeloma. Int J Cardiol. 2007 Jan 31;115(1):e29-30. Epub 2006 Oct 17.
[3]	Chinen K , Fujioka Y. Severe pulmonary hypertension caused by smoldering plasma cell myeloma : an autopsy case of POEMS syndrome . Case reports in medicine 2012; doi .10.1155/2012/836893
[4]	Dispenzieri A, Kyle RA, Lacy MQ et al . POEMS syndrome : definitions and long-term outcome . Blood 2003; 101: 2496 -2506
[5]	Ribadeau-Dumas S, Tillie-Leblond I, Rose C, et al. Pulmonary hypertension associated with POEMS syndrome. Eur Respir J. 1996;9:1760-1762
[6]	Rose C, Zandecki M, Copin MC, et al. POEMS syndrome: report on six patients with unusual clinical signs, elevated levels of cytokines, macrophage involvement and chromosomal aberrations of bone marrow plasma cells. Leukemia. 1997;11:1318-1323
[7]	Younis TH. Reversible pulmonary hypertension and thalidomide therapy for multiple myeloma. British Journal of Haematology 121, 191–192, 2003
[8]	Antonioli E , Nozzoli C, Gianfaldoni G et al. Pulmonary hypertension related to thalidomide therapy in refractory multiple myeloma Ann Oncol (November 2005) 16(11): 1849-1850.
[9]	Rostagno C, Ciolli S. Transient severe symptomatic pulmonary hypertension as onset symptom in multiple myeloma. Ann Haematol 2006;85:627-8
[10]	Dingli D; Utz JP Gertz MA. Pulmonary hypertension in patients with amyloidosis . Chest 2001; 120: 1736-8
[11]	Elice F, Fink L, Tricot G, BarlogieB, Zangari M. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitor abnormality associated with an increased risk of venous thromboembolism. Br J Haematol 2006; 134: 399–405
[12]	Kristinsson SY, Fears TR, Gridley G, Turesson I, Mellqvist UH, Bjorkholm M, et al. Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood. 2008; 112(9):3582-6.
[13]	Zangari M, Saghafifar F, Anaissie E, et al Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis 2002; 13: 187-192.
[14]	Corso A, Lorenzi A, Terulla V, et al Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone. Ann Hematol 2004; 83: 588-591.
[15]	Bardwick PA, Zvaifler NJ, Gill GN, Newman D, Greenway GD, Resnick DL. Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: the POEMS syndrome: report on two cases and a review of the literature. Medicine. 1980;59:311-322
[16]	Soubrier MJ, Dubost JJ, Sauvezie BJ. POEMS syndrome: a study of 25 cases and a review of the literature. French Study Group on POEMS syndrome. Am J Med. 1994;97:543-553
[17]	Yaqub S, Moder KG, Lacy MQ . Severe , reveversible pulmonary hypertension in a patient with monoclonal gammopathy and features of dermatomyosistis. Mayo Clin Proc 2004; 79: 687-9
[18]	Lesprit P, Godeau B, Authier FJ, et al. Pulmonary hypertension in POEMS syndrome: a new feature mediated by cytokines. Am J Respir Crit Care Med. 1998;157:907-911
[19]	Feinberg L, Temple D, de Marchena E, Patarca R, Mitrani A. Soluble immune mediators in POEMS syndrome with pulmonary hypertension: case report and review of the literature. Crit Rev Oncog. 1999;10:293-302
[20]	Paciocco G, Bossone E, Erba H, Rubenfire M. Reversible pulmonary hypertension in POEMS syndrome: another etiology of triggered pulmonary vasculopathy? Can J Cardiol. 2000;16:1007-101
[21]	Lesprit P, Authier FJ, Gherardi R, et al. Acute arterial obliteration: a new feature of the POEMS syndrome? Medicine. 1996;75:226-232
[22]	Watanabe O, Maruyama I, Arimura K, et al. Overproduction of vascular endothelial growth factor/vascular permeability factor is causative in Crow-Fukase (POEMS) syndrome. Muscle Nerve. 1998;21:1390-1397
[23]	Soubrier M, Dubost JJ, Serre AF, et al. Growth factors in POEMS syndrome: evidence for a marked increase in circulating vascular endothelial growth factor. Arthritis Rheum. 1997;40:786-78
[24]	Villa A, Mazzola AA, Ghio S, Martinoli E, Marino P. Reversible pulmonary hypertension related to thalidomide treatment for multiple myeloma. Case Rep Oncol. 2011 Sep;4(3):487-9. doi: 10.1159/000333016. Epub 2011 Sep 28
[25]	Cavo M, Zamagni E, Tosi P et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematology2004; 89: 826–831.
[26]	C. Lafaras, E. Mandala, E. Verrou, D. Platogiannis, N. Barbetakis, T. Bischiniotis K. Zervas Non-thromboembolic pulmonary hypertension in multiple myeloma, after thalidomide treatment: A pilot study. Annals of Oncology 19: 1765–1769, 200
[27]	Pepke-Zaba J, Morrell NW. The endothelin system and its role in pulmonary arterial hypertension (PAH). Thorax 2005; 60(6): 443–444.
[28]	Steiner MK, Preston IR, Klinger JR, Hill NS. Pulmonary hypertension: invale nitric oxide, sildenafil and natriuretic peptides. Curr Opin Pharmacol 2005; 5(3):245–250.
[29]	Hattori Y, Shimoda M, Okamoto S et al. Pulmonary hypertension and thalidomide therapy in multiple myeloma. Br J Haematol 2005; 128: 885–888.

Cite This Article

Plain Text BibTeX RIS

APA Style

Carlo Rostagno, Rostagno Perfetto. (2013). Pulmonary Hypertension and Multiple Myeloma. Clinical Medicine Research, 2(4), 73-76. https://doi.org/10.11648/j.cmr.20130204.17

Copy | Download

ACS Style

Carlo Rostagno; Rostagno Perfetto. Pulmonary Hypertension and Multiple Myeloma. Clin. Med. Res. 2013, 2(4), 73-76. doi: 10.11648/j.cmr.20130204.17

Copy | Download

AMA Style

Carlo Rostagno, Rostagno Perfetto. Pulmonary Hypertension and Multiple Myeloma. Clin Med Res. 2013;2(4):73-76. doi: 10.11648/j.cmr.20130204.17

Copy | Download

@article{10.11648/j.cmr.20130204.17,
  author = {Carlo Rostagno and Rostagno Perfetto},
  title = {Pulmonary Hypertension and Multiple Myeloma},
  journal = {Clinical Medicine Research},
  volume = {2},
  number = {4},
  pages = {73-76},
  doi = {10.11648/j.cmr.20130204.17},
  url = {https://doi.org/10.11648/j.cmr.20130204.17},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.cmr.20130204.17},
  abstract = {The relationships between pulmonary hypertension multiple myeloma, monoclonal protein and finally drug treatment of plasma cell diseases are complex and not fully elucidated. Pulmonary hypertension has been reported as a rare complication of multiple myeloma (MM), more frequently in patients with POEMS syndrome. More recently pulmonary hypertension has been described during thalidomide treatment for refractory MM. We report a case of severe pulmonary hypertension associated with MM, pleural and cardiac amyloidosis. A revision of literature follows.},
 year = {2013}
}

Copy | Download

TY  - JOUR
T1  - Pulmonary Hypertension and Multiple Myeloma
AU  - Carlo Rostagno
AU  - Rostagno Perfetto
Y1  - 2013/07/20
PY  - 2013
N1  - https://doi.org/10.11648/j.cmr.20130204.17
DO  - 10.11648/j.cmr.20130204.17
T2  - Clinical Medicine Research
JF  - Clinical Medicine Research
JO  - Clinical Medicine Research
SP  - 73
EP  - 76
PB  - Science Publishing Group
SN  - 2326-9057
UR  - https://doi.org/10.11648/j.cmr.20130204.17
AB  - The relationships between pulmonary hypertension multiple myeloma, monoclonal protein and finally drug treatment of plasma cell diseases are complex and not fully elucidated. Pulmonary hypertension has been reported as a rare complication of multiple myeloma (MM), more frequently in patients with POEMS syndrome. More recently pulmonary hypertension has been described during thalidomide treatment for refractory MM. We report a case of severe pulmonary hypertension associated with MM, pleural and cardiac amyloidosis. A revision of literature follows.
VL  - 2
IS  - 4
ER  -

Copy | Download

Author Information

Carlo Rostagno

Department of Sperimental and Clinical Medicine, Critic Area Section, University of Florence, Italy
Rostagno Perfetto

Department of Sperimental and Clinical Medicine, Critic Area Section, University of Florence, Italy

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Carlo Rostagno, Rostagno Perfetto. (2013). Pulmonary Hypertension and Multiple Myeloma. Clinical Medicine Research, 2(4), 73-76. https://doi.org/10.11648/j.cmr.20130204.17

Copy | Download

ACS Style

Carlo Rostagno; Rostagno Perfetto. Pulmonary Hypertension and Multiple Myeloma. Clin. Med. Res. 2013, 2(4), 73-76. doi: 10.11648/j.cmr.20130204.17

Copy | Download

AMA Style

Carlo Rostagno, Rostagno Perfetto. Pulmonary Hypertension and Multiple Myeloma. Clin Med Res. 2013;2(4):73-76. doi: 10.11648/j.cmr.20130204.17

Copy | Download

@article{10.11648/j.cmr.20130204.17,
  author = {Carlo Rostagno and Rostagno Perfetto},
  title = {Pulmonary Hypertension and Multiple Myeloma},
  journal = {Clinical Medicine Research},
  volume = {2},
  number = {4},
  pages = {73-76},
  doi = {10.11648/j.cmr.20130204.17},
  url = {https://doi.org/10.11648/j.cmr.20130204.17},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.cmr.20130204.17},
  abstract = {The relationships between pulmonary hypertension multiple myeloma, monoclonal protein and finally drug treatment of plasma cell diseases are complex and not fully elucidated. Pulmonary hypertension has been reported as a rare complication of multiple myeloma (MM), more frequently in patients with POEMS syndrome. More recently pulmonary hypertension has been described during thalidomide treatment for refractory MM. We report a case of severe pulmonary hypertension associated with MM, pleural and cardiac amyloidosis. A revision of literature follows.},
 year = {2013}
}

Copy | Download

TY  - JOUR
T1  - Pulmonary Hypertension and Multiple Myeloma
AU  - Carlo Rostagno
AU  - Rostagno Perfetto
Y1  - 2013/07/20
PY  - 2013
N1  - https://doi.org/10.11648/j.cmr.20130204.17
DO  - 10.11648/j.cmr.20130204.17
T2  - Clinical Medicine Research
JF  - Clinical Medicine Research
JO  - Clinical Medicine Research
SP  - 73
EP  - 76
PB  - Science Publishing Group
SN  - 2326-9057
UR  - https://doi.org/10.11648/j.cmr.20130204.17
AB  - The relationships between pulmonary hypertension multiple myeloma, monoclonal protein and finally drug treatment of plasma cell diseases are complex and not fully elucidated. Pulmonary hypertension has been reported as a rare complication of multiple myeloma (MM), more frequently in patients with POEMS syndrome. More recently pulmonary hypertension has been described during thalidomide treatment for refractory MM. We report a case of severe pulmonary hypertension associated with MM, pleural and cardiac amyloidosis. A revision of literature follows.
VL  - 2
IS  - 4
ER  -

Copy | Download